Difficult to know whether Davis was intimating that Acadia has acquired full rights to NNZ-2591 or if he simply failed to make clear that the NNZ-2591 rights acquired by Acadia are limited to Rett syndrome and Fragile-X.
Acadia, page-370
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.92 |
Change
0.860(4.51%) |
Mkt cap ! $2.433B | |||
| Open | High | Low | Value | Volume |
| $19.58 | $19.98 | $19.47 | $1.308M | 66.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 501 | $19.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.95 | 1168 | 9 |
View Market Depth
| Last trade - 10.37am 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.06 |
Change
0.860 ( 4.94 %) |
||||
| Open | High | Low | Volume | ||
| $19.56 | $20.08 | $19.53 | 19739 | ||
| Last updated 10.56am 14/05/2024 ? | |||||
| NEU (ASX) Chart |